Geode Capital Management
CAMP icon

Geode Capital Management’s CAMP4 Therapeutics CAMP Stock Holding History

Geode Capital Management’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.69M Buy
382,821
+46,528
+14% +$221K ﹤0.01% 3189
2025
Q4 		$2.06M Buy
336,293
+275,922
+457% +$1.17M ﹤0.01% 3159
2025
Q3 		$181K Sell
60,371
-14,828
-20% -$27.5K ﹤0.01% 3956
2025
Q2 		$109K Sell
75,199
-84,403
-53% -$168K ﹤0.01% 4035
2025
Q1 		$638K Buy
159,602
+14,516
+10% +$70.2K ﹤0.01% 3458
2024
Q4 		$757K Buy
+145,086
New +$1.19M ﹤0.01% 3464

Other funds holding CAMP

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management's CAMP Position: Q1 2026 in Review

Geode Capital Management increased its CAMP4 Therapeutics (CAMP) stake by 14% in Q1 2026, buying an estimated $221K and bringing the position to 382,821 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #3189.

Geode Capital Management first reported a position in CAMP in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.06M in Q4 2025. 46 funds tracked by Wall St. Rank hold CAMP as of Q1 2026.

  • Geode Capital Management held 382,821 shares of CAMP4 Therapeutics worth $1.69M as of Q1 2026.
  • Geode Capital Management bought 46,528 CAMP4 Therapeutics shares in Q1 2026, an estimated $221K.
  • CAMP4 Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3189 holding.
  • Geode Capital Management first reported a position in CAMP4 Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Geode Capital Management's CAMP4 Therapeutics position peaked at $2.06M in Q4 2025.
  • 46 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.